Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyridoxamine + hesperidin + resveratrol
- Development stage
- Preclinical
- Lead developer
- Erasmus MC
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The MGO-lowering cocktail is an experimental combination therapy consisting of pyridoxamine, hesperidin, and resveratrol. It is designed to target and reduce endogenous levels of methylglyoxal (MGO), a reactive glycolytic byproduct that accumulates during chronic hyperglycemia and aging, leading to advanced glycation endproducts (AGEs) and vascular complications. Mechanistically, pyridoxamine acts as a direct scavenger of MGO, while hesperidin and resveratrol synergistically enhance the enzymatic detoxification of MGO by upregulating glyoxalase 1 (GLO1) expression, likely via Nrf2 pathway activation. In preclinical models of type 1 diabetes, this cocktail has been shown to prevent the elevation of plasma MGO, improve aortic distensibility, and restore endothelial function, offering a promising therapeutic strategy for mitigating diabetes-related cardiovascular complications.
- Other names
- methylglyoxal-lowering cocktailMGO-lowering cocktail
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)FYN (Proto-oncogene tyrosine-protein kinase Fyn)GLO1 (Glyoxalase 1)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PKA (Cyclic amp-dependent protein kinase)PDE (Phosphodiesterase family)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on pyridoxamine + hesperidin + resveratrol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyridoxamine + hesperidin + resveratrol.